- About the VMC
- Pet Owners
- Farm Animal Owners
- Horse Owners
- Clinical Trials Office
The purpose of this trial evaluating three structurally related chemotherapy drugs to to define their safety, pharmacokinetics, and pharmacodynamic modulation.
Lymphoma is one of the most common cancers in dogs, accounting for 7% to 24% of all canine cancers and having an estimated annual incidence of 13 to 24 cases per 100,000 dogs at risk. Although most dogs with lymphoma respond initially to current chemotherapy drugs, most eventually develop drug resistance. The indenoisoquinolines represent a new class of topoisomerase I inhibitors. This trial is divided into 2 steps: (1) dose escalation, tolerability, pharmacokinetic/pharmacodynamic study and (2) a cohort expansion at the maximally tolerated dose to extend the PK-PD profile of each agent. Study objectives are to distinguish the toxicity profiles of these agents and determine a difference in biological activity if one exists. The results of this study will aid in future design and implementation of trials using these indenoisoquinolines.
The following are required for enrollment and can be performed at the OSU-VMC < 7 days before drug administration and are at cost to the owner:
The study sponsor covers all study associated costs once enrolled in the study as well as provide clients with a $1,000 OSU-CVM account credit for any further veterinary care for their pet.